Frontiers in Aging Neuroscience (Aug 2023)
Clinical features of progressive supranuclear palsy
- Yafei Wen,
- Qijie Yang,
- Bin Jiao,
- Bin Jiao,
- Bin Jiao,
- Bin Jiao,
- Bin Jiao,
- Weiwei Zhang,
- Jingyi Lin,
- Yuan Zhu,
- Qian Xu,
- Qian Xu,
- Hui Zhou,
- Ling Weng,
- Ling Weng,
- Xinxin Liao,
- Yafang Zhou,
- Junling Wang,
- Jifeng Guo,
- Jifeng Guo,
- Jifeng Guo,
- Jifeng Guo,
- Xinxiang Yan,
- Xinxiang Yan,
- Xinxiang Yan,
- Xinxiang Yan,
- Hong Jiang,
- Beisha Tang,
- Beisha Tang,
- Beisha Tang,
- Beisha Tang,
- Lu Shen,
- Lu Shen,
- Lu Shen,
- Lu Shen,
- Lu Shen,
- Lu Shen
Affiliations
- Yafei Wen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Qijie Yang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Bin Jiao
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Bin Jiao
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Bin Jiao
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, China
- Bin Jiao
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- Bin Jiao
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Weiwei Zhang
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, China
- Jingyi Lin
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, China
- Yuan Zhu
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Qian Xu
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Qian Xu
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Hui Zhou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Ling Weng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Ling Weng
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Xinxin Liao
- Department of Geriatrics Neurology, Xiangya Hospital, Central South University, Changsha, China
- Yafang Zhou
- Department of Geriatrics Neurology, Xiangya Hospital, Central South University, Changsha, China
- Junling Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Jifeng Guo
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Jifeng Guo
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Jifeng Guo
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- Jifeng Guo
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Xinxiang Yan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Xinxiang Yan
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Xinxiang Yan
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- Xinxiang Yan
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Beisha Tang
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Beisha Tang
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- Beisha Tang
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Lu Shen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Lu Shen
- National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, China
- Lu Shen
- Engineering Research Center of Hunan Province in Cognitive Impairment Disorders, Central South University, Changsha, China
- Lu Shen
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- Lu Shen
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Lu Shen
- Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China
- DOI
- https://doi.org/10.3389/fnagi.2023.1229491
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundProgressive supranuclear palsy (PSP) is a clinically heterogenous atypical parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is challenging but essential. This study aims to characterize the clinical manifestations, magnetic resonance imaging (MRI), and longitudinal MRI changes of PSP in China.MethodClinical and MRI presentations were compared among 150 cases with PSP. Then the longitudinal MRI changes among 20 patients with PSP were further explored. Additionally, a series of midbrain-based MRI parameters was compared between PSP-P and PD.ResultsThroughout the course of the disease, there were differences in the symptoms of the fall and hand tremor between the PSP-RS and PSP-P. There were significant differences in the six midbrain-based MRI parameters between the PSP-RS and the PSP-P, including hummingbird sign, midbrain diameter, midbrain to pons ratio (MTPR), midbrain area, midbrain area to pons area ratio (Ma/Pa), and midbrain tegmental length (MBTegm). Longitudinal MRI studies revealed that the annual rel.ΔMTPR and rel.Δ (Ma/Pa) for PSP were 5.55 and 6.52%, respectively; additionally, PSP-RS presented a higher decline rate than PSP-P. Moreover, MTPR ≤0.56, midbrain diameter ≤ 0.92, midbrain area ≤ 1.00, and third ventricle width ≤ 0.75 could identify PSP-P from PD.ConclusionPSP-P differs from PSP-RS regarding clinical manifestations, MRI, and longitudinal MRI changes. MRI parameters could be potential imaging markers to identify PSP-P from PD.
Keywords
